Cangrelor
- Generic Name
- Cangrelor
- Brand Names
- Kengreal, Kengrexal
- Drug Type
- Small Molecule
- Chemical Formula
- C17H25Cl2F3N5O12P3S2
- CAS Number
- 163706-06-7
- Unique Ingredient Identifier
- 6AQ1Y404U7
- Background
Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset and offset of action. Cangrelor was approved by the FDA in June 2015 for intravenous application.
- Indication
For use as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.
- Associated Conditions
- Coronary Revascularization, Peri-procedural Myocardial Infarction, Thrombosis (Stent Thrombosis)
- Associated Therapies
- -
Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2012-01-18
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 67
- Registration Number
- NCT00699504
- Locations
- 🇺🇸
Charles River Clinical Services NW, Tacoma, Washington, United States
Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.
- First Posted Date
- 2006-10-06
- Last Posted Date
- 2014-05-05
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 5364
- Registration Number
- NCT00385138
- Locations
- 🇺🇸
Innovis Health, Fargo, North Dakota, United States
Pharmacokinetics/Pharmacodynamics (PK/PD) of Cangrelor
- Conditions
- First Posted Date
- 2005-02-01
- Last Posted Date
- 2011-08-16
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 40
- Registration Number
- NCT00102674
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.